Last: | |||
Change: | Change(%): | ||
Volume: | Open: | ||
High: | Low: | ||
52Wk High: | 52Wk Low: |
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. The Company’s lead product candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist that is being evaluated for overactive bladder (OAB).